Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

161
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
161
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anterior thigh muscle thickness normalized by body mass index is associated with falls in community-dwelling adults.

Clinical nutrition ESPEN·2025
Same author

Revisiting the Barthel Index　- A Common Language for Activities of Daily Living With Timeless Value in the Digital Era.

Circulation journal : official journal of the Japanese Circulation Society·2025
Same author

Impact and management of integrated dysphagia rehabilitation within cardiac care programs for older patients with cardiovascular disease.

European geriatric medicine·2024
Same author

Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma.

Hematology reports·2024
Same author

A phase II Japanese trial of 90-minute rituximab infusion for untreated B-cell lymphoma.

Japanese journal of clinical oncology·2024
Same author

Overlapping states of AWGS muscle dysfunction and inverse feasibility of ADL recovery by rehabilitation in older inpatients.

Scientific reports·2022

Related Experiment Video

Updated: Apr 27, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

[Novel targeted therapy in multiple myeloma].

Tohru Izumi

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |July 15, 2014
    PubMed
    Summary

    New treatments for multiple myeloma (MM) are emerging, building on proteasome inhibitors and immunomodulatory drugs. This review explores novel agents for patients refractory to current therapies.

    Area of Science:

    • Hematology
    • Oncology
    • Pharmacology

    Context:

    • Multiple myeloma (MM) is a hematologic malignancy with improving but still limited treatment outcomes.
    • Current MM therapies include proteasome inhibitors (e.g., bortezomib) and immunomodulatory drugs (IMiDs) (e.g., thalidomide, lenalidomide).
    • Patient refractory to bortezomib and IMiDs face a poor prognosis, necessitating novel therapeutic strategies.

    Purpose:

    • To review novel therapeutic agents and mechanisms of action for multiple myeloma (MM).
    • To discuss emerging treatments for patients with MM who are refractory to established therapies.
    • To highlight the potential of new drug classes in improving MM patient outcomes.

    Summary:

    • Recent advances in understanding MM pathogenesis have led to new therapeutic agents.

    More Related Videos

    Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
    07:24

    Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

    Published on: December 13, 2018

    5.7K
    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
    09:41

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

    Published on: July 15, 2015

    8.2K

    Related Experiment Videos

    Last Updated: Apr 27, 2026

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
    05:32

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

    Published on: January 7, 2019

    6.1K
    Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
    07:24

    Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

    Published on: December 13, 2018

    5.7K
    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
    09:41

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

    Published on: July 15, 2015

    8.2K
  • Proteasome inhibitors and IMiDs have improved outcomes but do not offer a cure.
  • This review focuses on novel agents like monoclonal antibodies and deacetylase inhibitors for refractory MM.

    • Impact:

    • Identifies promising new therapeutic avenues for relapsed or refractory multiple myeloma.
    • Provides insights into the evolving landscape of MM treatment strategies.
    • Aims to guide future research and clinical application of novel agents in MM therapy.